PMID- 26149465
OWN - NLM
STAT- MEDLINE
DCOM- 20151215
LR  - 20150921
IS  - 1096-8652 (Electronic)
IS  - 0361-8609 (Linking)
VI  - 90
IP  - 10
DP  - 2015 Oct
TI  - A randomized comparison of once weekly epoetin alfa to extended schedule epoetin 
      or darbepoetin in chemotherapy-associated anemia.
PG  - 877-81
LID - 10.1002/ajh.24110 [doi]
AB  - Erythropoiesis-stimulating agents (ESAs) epoetin alfa (EA) and darbepoetin alfa 
      (DA) increase hemoglobin (Hb) levels and reduce red blood cell (RBC) transfusion 
      requirements in patients with cancer chemotherapy-associated anemia (CAA). 
      Extended-interval ESA dosing (administration less than once weekly) is common 
      with DA, but previous studies suggested that EA might also be administered less 
      often than weekly. In this multicenter prospective trial, 239 CAA patients with 
      Hb <10.5 g/dL were randomized to receive EA 40,000 U subcutaneously once weekly 
      ("40K" arm), EA 80,000 U every 3 weeks ("80K"), EA 120,000 U every 3 weeks 
      ("120K" arm), or DA 500 mcg every 3 weeks ("DA"), for 15 weeks. The primary 
      endpoint was the proportion of patients achieving Hb >/= 11.5 g/dL or increment of 
      Hb > 2.0 g/dL from baseline without transfusion. Secondary endpoints included 
      transfusion requirements, adverse events (AEs), and patient-reported outcomes 
      (PROs). There were no significant differences between treatment arms in the 
      proportion of patients achieving Hb response (68.9% for 40K, 61.7% for 80K, 65.5% 
      for 120K, and 66.7% for DA; P > 0.41 for all comparisons) or requiring RBC 
      transfusion, but the median Hb increment from baseline was higher in the 40K and 
      DA arms compared to the two extended dosing EA arms, and Hb response was achieved 
      soonest in the weekly EA arm. There were no differences in PROs or AEs. The 
      FDA-approved schedules tested-weekly EA 40,000 U, and every 3 week DA 500 mcg-are 
      reasonable standards for CAA therapy.
CI  - (c) 2015 Wiley Periodicals, Inc.
FAU - Steensma, David P
AU  - Steensma DP
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 
      Massachusetts.
FAU - Dakhil, Shaker R
AU  - Dakhil SR
AD  - Cancer Center of Kansas, Wichita, Kansas.
FAU - Novotny, Paul J
AU  - Novotny PJ
AD  - Cancer Center Statistics, Mayo Clinic, Rochester, Minnesota.
FAU - Sloan, Jeff A
AU  - Sloan JA
AD  - Cancer Center Statistics, Mayo Clinic, Rochester, Minnesota.
FAU - Johnson, David B
AU  - Johnson DB
AD  - Cancer Center of Kansas, Wichita, Kansas.
FAU - Anderson, Daniel M
AU  - Anderson DM
AD  - Minnesota CGOP, Saint Paul, Minnesota.
FAU - Mattar, Bassam I
AU  - Mattar BI
AD  - Cancer Center of Kansas, Wichita, Kansas.
FAU - Moore, Dennis F Jr
AU  - Moore DF Jr
AD  - Cancer Center of Kansas, Wichita, Kansas.
FAU - Nikcevich, Daniel
AU  - Nikcevich D
AD  - St. Mary's Duluth Clinic, Duluth, Minnesota.
FAU - Loprinzi, Charles L
AU  - Loprinzi CL
AD  - Department of Oncology, Mayo Clinic, Rochester, Minnesota.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150814
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
RN  - 0 (Hematinics)
RN  - 0 (Hemoglobins)
RN  - 15UQ94PT4P (Darbepoetin alfa)
RN  - 64FS3BFH5W (Epoetin Alfa)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anemia/blood/*chemically induced/*drug therapy
MH  - Darbepoetin alfa/*administration & dosage
MH  - Epoetin Alfa/*administration & dosage
MH  - Female
MH  - Hematinics/*administration & dosage
MH  - Hemoglobins/metabolism
MH  - Humans
MH  - Male
MH  - Neoplasms/*drug therapy
EDAT- 2015/07/08 06:00
MHDA- 2015/12/17 06:00
CRDT- 2015/07/08 06:00
PHST- 2015/06/19 00:00 [received]
PHST- 2015/06/29 00:00 [revised]
PHST- 2015/07/02 00:00 [accepted]
PHST- 2015/07/08 06:00 [entrez]
PHST- 2015/07/08 06:00 [pubmed]
PHST- 2015/12/17 06:00 [medline]
AID - 10.1002/ajh.24110 [doi]
PST - ppublish
SO  - Am J Hematol. 2015 Oct;90(10):877-81. doi: 10.1002/ajh.24110. Epub 2015 Aug 14.